NR4A1 and cancer: Moreover, subgroup analysis revealed contradictory findings, with one study reporting greater benefit in women with hormone receptor negative (triple negative) disease [64] and the other study suggesting that women with hormone receptor positive cancer were more likely to benefit [63].